Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 10:15PM GMT
Release Date Price: $11.09
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Okay. Let's go ahead and get started. So welcome to the afternoon session of the Monday of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Amicus Therapeutics and presented on behalf of the company, we have CEO, Brad Camel. Brad.

Bradley L. Campbell
Amicus Therapeutics, Inc. - CEO, President & Director

Thank you, Anupam. Good afternoon, everybody. Great to see everybody live and in living color here at JPMorgan. Thanks to Anupam and JPMorgan for inviting us here. And thanks for also setting expectations that it was going to rain all day. I don't know if anybody's been outside. It's actually bright and sunny outside. So well done, setting low expectations and meeting and beating them. I will be making certain forward-looking statements, so I'll refer you to my safe harbor statement.

So just as a reminder,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot